- Lawmakers request detailed information on Merck's research oversight and safeguards related to its China operations.
Abivax prices its oversubscribed and upsized $800M ADS offering at $125 per share, boosting gross proceeds and extending its cash runway into Q2 2029
- Abivax earlier halted Paris trading to finalize allocations and pricing for its ongoing U.S. ADS public offering.
Can-Fite BioPharma's Namodenoson meets primary safety endpoint in Phase 2a advanced pancreatic cancer study
- Company plans Phase 2b trial combining Namodenoson with chemotherapy after Phase 2a showed durable survival outcomes.